PEGASYS PLUS AMANTADINE AND PEGASYS PLUS AMANTADINE PLUS RIBAVIRIN

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的主要目的是探讨Pegasys联合金刚烷胺和Pegasys联合金刚烷胺联合利巴韦林作为慢性HCV感染患者初始治疗的有效性和安全性，以及rebetron与Pegasys联合CellCept的比较。本研究中的其他药物经美国食品和药物管理局（FDA）批准用于以下目的：(1)利巴韦林作为治疗下呼吸道感染的吸入剂，已作为Virazole上市多年。最近，利巴韦林已被FDA批准为retol，与另一种称为干扰素A（干扰素α -2b）的药物一起使用。内含子A和rebel的组合称为Rebetron；(2) Rebetron获FDA批准用于丙型肝炎感染患者；(3) CellCept已被FDA批准用于帮助接受肾脏或心脏移植的患者预防器官排斥反应；(4)金刚烷胺用于防治甲型流感病毒感染引起的呼吸道感染。初步研究表明，当联合使用时，CellCept和金刚烷胺可能对丙型肝炎感染有效，尽管它们尚未得到FDA的批准。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to investigate the effectiveness and safety of Pegasys plus amantadine, and Pegasys plus amantadine plus ribavirin, and comparison of rebetron with Pegasys plus CellCept, as initial treatment in patients with chronic HCV infection. The additional drugs in this study are approved by the Food and Drug Administration (FDA) to be used for the followoing purposes: (1) ribavirin has been marketed as Virazole for many years as an inhaler for the treatment of lower respiratory tract infections. More recently, ribavirin has been approved by the FDA as Rebetol, to be used with another medication called Intron A (interferon alfa-2b). The combination of Intron A and Rebetol is called Rebetron; (2) Rebetron is approved by the FDA for patients with hepatitis C infection; (3) CellCept has been approved by the FDA to help prevent organ rejection in patients receiving a kidney or heart transplant; and (4) amantadine is used for the prevention and treatment of respiratory tract infections caused by influenza A virus infections. Preliminary studies suggest that when used in combination, CellCept and amantadine may be useful against hepatitis C infections, although they are not yet approved by the FDA for this use.